+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Narcolepsy Type 1 NT1 is a sleep disorder characterized by excessive daytime sleepiness and sudden muscle weakness while conscious, known as cataplexy. This trial evaluates the safety and tolerability of TAK-360 in adults with NT1. Participants must stop their current NT1 medications before starting the study treatment. They may be randomly assigned to receive either TAK-360 or a placebo, which looks identical but contains no active medicine. The trial is sponsored by Takeda and uses a randomized, double-blind design. Participants will take TAK-360 or matching placebo tablets orally. The study includes multiple parts where participants receive either TAK-360 or placebo in a parallel design. After the treatment period lasting up to about 28 weeks, participants will be monitored for an additional two weeks. Following study treatment, participants can resume their usual NT1 medications. Throughout the trial, participants will visit the clinic multiple times for evaluations. Researchers will assess treatment-emergent adverse events, sleep latency using the Maintenance of Wakefulness Test, sleepiness levels with the Epworth Sleepiness Scale, and weekly cataplexy rates. Safety and tolerability will be closely monitored, and participants usual care will continue after the study ends.

Age: 18Years - 70YearsAll GendersPhase 2
18 locations
R

Actively Recruiting

Narcolepsy Type 2 NT2 is a lifelong condition causing excessive daytime sleepiness and difficulty staying awake, which can disrupt daily activities and quality of life. Researchers are studying TAK-360, a drug that acts like the brain chemical orexin, to evaluate its safety, tolerability, and potential to help adults with NT2 stay awake. This Phase 2 trial also aims to determine the right dosage of TAK-360. Participants will be randomly assigned to receive either TAK-360 tablets or matching placebo tablets orally for 4 weeks. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo during the treatment period. Throughout the study, participants will be monitored for treatment-emergent adverse events up to 15 weeks. Researchers will measure changes from baseline to week 4 in sleepiness using the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test. This helps evaluate how well TAK-360 helps participants stay awake and alert during the day.

Age: 18Years - 70YearsAll GendersPhase 2
52 locations
L

Actively Recruiting

Central hypersomnia conditions, including narcolepsy types 1 and 2 and idiopathic hypersomnia, cause excessive daytime sleepiness due to the brains difficulty in keeping a person awake. Narcolepsy type 1 includes sudden muscle weakness called cataplexy, while type 2 does not. Idiopathic hypersomnia causes extreme sleepiness without refreshment from naps. This long-term extension study evaluates how well participants tolerate and how safe the study drug TAK-360 is when taken over an extended period. Participants who finished earlier TAK-360 studies can join this trial. Everyone will receive TAK-360 tablets, either continuing their previous dose or switching to the closest available dose. Those who had placebo in prior studies will receive TAK-360 now. Placebo tablets may be given during this study to keep dosing blind but only as needed. Treatment will last for up to approximately five years. Participants will visit the clinic multiple times throughout the study for assessments. Researchers will monitor safety by tracking adverse events and measure sleepiness, sleep latency, and narcolepsy symptoms using various scales and participant diaries. These evaluations will continue over the study duration to understand long-term effects of TAK-360 in central hypersomnia conditions.

Age: 18Years - 71YearsAll GendersPhase 2Phase 3
31 locations